ROCKVILLE, Md., April 7 /PRNewswire-FirstCall/ -- Novavax, Inc. announced today that it has appointed James F. Young, Ph.D., to its Board of Directors. Dr. Young will be an independent Board Member effective immediately.
“We are very pleased to welcome such an accomplished and distinguished member of the biotech industry to Novavax’s Board of Directors,” said Stan Erck, Executive Chairman of Novavax Board of Directors. “His extensive experience and knowledge in the vaccine arena will be a tremendous advantage to Novavax as the company moves forward to advance our pipeline products.”
About Novavax
Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website: www.novavax.com.
Novavax, Inc.
